A study looking at the genes in lymphoma cells (MaPLe)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Blood cancers
High grade lymphoma
Non-Hodgkin lymphoma





This study is collecting information about the genes in lymphoma cells. This technique is called molecular profiling. The study is recruiting people with either of the following types of non Hodgkin lymphoma (NHL)

More about this trial

Doctors usually treat NHL with chemotherapy and sometimes a type of biological therapy called a monoclonal antibody. Researchers are looking for ways to improve treatment for lymphoma.

Earlier research has suggested that changes to genes in certain types of lymphoma can encourage the lymphoma to grow. It is possible that new treatments will be able to target these gene changes and may work particularly well in people who have lymphoma with these changes.

The aims of this study are to

  • Look at gene changes in lymphoma to identify who may be suitable for new targeted treatments
  • Collect information about these gene changes, the treatment people then have and how well the treatments work
  • See whether it is possible to carry out molecular profiling of lymphoma in the National Health Service

You do not have any treatment as a result of taking part in this study. The researchers will carry out molecular profiling on your lymphoma cells and this information is passed on to your doctor who will discuss the results with you. This may play a part in which treatments your doctors recommend for you in the future.

Who can enter

You may be able to join this study if all of the following apply

  • You are having tests for, or have a diagnosis of, either diffuse large B cell lymphoma or grade 3b follicular lymphoma
  • Your doctor thinks that you may be suitable for targeted therapy either now or in the future
  • There is a sample (biopsy Open a glossary item) of your lymphoma that is available for the study team to look at (this may have been taken either when you were first diagnosed or if your lymphoma has come back)

Trial design

This study will recruit over 3,000 people. The study team will send a sample (biopsy) of your lymphoma and a blood sample to a laboratory in Leeds for molecular profiling. This can take about 4 weeks to carry out.

The results of your molecular profiling are sent back to your doctor and they will discuss these results and what they may mean for you.

Your doctor may use some of these results to help them decide on treatment in the future. The study team will collect information about the treatment you have and how your lymphoma responds to see how this relates to any gene changes.

The researchers will ask your permission to keep some of your tissue sample in storage to use in future research. This is unlikely to benefit you, but it may be used to learn more about lymphoma. If you don’t want to give these samples for future research, you don’t have to. You can still take part in the main study.

Hospital visits

You do not have any extra hospital visits as a result of taking part in this study.

Side effects

As this study does not involve a treatment, there are no side effects associated with taking part.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Peter Johnson

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Southampton University Hospitals NHS Trust

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

Currently rated: 2.1 out of 5 based on 8 votes
Thank you!
We've recently made some changes to the site, tell us what you think